doc. MUDr. Alexandr Poprach, Ph.D.
Associate professor, Comprehensive Cancer Care Department
Total number of publications: 144
2024
-
11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)
BMC Cancer, year: 2024, volume: 24, edition: 1, DOI
-
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
New England Journal of Medicine, year: 2024, volume: 391, edition: 8, DOI
-
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Targeted Oncology, year: 2024, DOI
-
Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
CASE REPORTS IN ONCOLOGY, year: 2024, volume: 17, edition: 1, DOI
-
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Targeted Oncology, year: 2024, DOI
-
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
Targeted Oncology, year: 2024, volume: 19, edition: 2, DOI
-
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Targeted Oncology, year: 2024, DOI
-
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Cancer immunology, immunotherapy, year: 2024, volume: 73, edition: 8, DOI
-
Transmembrane glycoprotein GPNMB is a candidate predictive biomarker and potentially a therapeutic target in metastatic renal cell carcinoma
Year: 2024, type: Conference abstract
2023
-
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
Targeted Oncology, year: 2023, volume: 18, edition: November 2023, DOI